Extravasation of oxaliplatin: an infrequent and irritant toxicity

Clin Transl Oncol. 2009 Feb;11(2):114-6. doi: 10.1007/s12094-009-0324-z.

Abstract

Oxaliplatin has been classified as an irritant drug. Less than 10 cases of oxaliplatin extravasation through a central venous access have been described to date. We present a case of extravasation through a central venous access, of the highest dose (165 mg) of oxaliplatin reported to date. We confirmed the irritant effect, and full recovery from toxicity was achieved. We describe the treatment administered and offer a review of literature.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Extravasation of Diagnostic and Therapeutic Materials / diagnosis*
  • Extravasation of Diagnostic and Therapeutic Materials / pathology
  • Extravasation of Diagnostic and Therapeutic Materials / therapy
  • Female
  • Humans
  • Organoplatinum Compounds / administration & dosage
  • Organoplatinum Compounds / adverse effects*
  • Oxaliplatin
  • Rectal Neoplasms / drug therapy

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Oxaliplatin